NCT02497898尚未招募2 期
A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 1,000
- 主要终点
- Progression-Free-Survival (PFS)
研究概览
简要总结
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
详细描述
Autologous cytokine-induced killer (CIK) cells transfusion(>2*10^9 cells count) within 2 weeks after regular chemotherapy every 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy
排除标准
- •patients refuse the therapy or have no tolerance for the therapy
结局指标
主要结局
Progression-Free-Survival (PFS)
时间窗: 1 month
次要结局
- Overall Survival (OS)(1 month)
研究者
相似试验
进行中（未招募）
2 期
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal CancerColorectal NeoplasmsNCT02487992The First People's Hospital of Changzhou1,200
已完成
4 期
Chemotherapy Combined With CIK Treating Colon CancerColorectal CancerCytokine-induced Killer CellsPostoperative ComplicationsSurvivalNCT03084809China Meitan General Hospital46
招募中
不适用
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell DysfunctionB-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoid LeukemiaNCT06389305Beijing GoBroad Hospital213
Unknown
2 期
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal CancerEsophageal NeoplasmsNeoplasmsDigestive System NeoplasmsEsophageal CancerNCT02644863Shenzhen Hornetcorn Bio-technology Company, LTD60
Unknown
3 期
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR MutationLung CancerNCT01996098Sun Yat-sen University318